ClinicalTrials.gg
CompletedNCT04902781Updated Oct 29, 2025

Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia

A Phase 2/3 interventional study of AT-007 and Placebo in Classic Galactosemia, sponsored by Applied Therapeutics, Inc.. Completed at 3 sites in United States. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-10-29.

Sponsored by Applied Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2023, 3 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Study summary

This study is designed to assess the clinical benefit as well as the safety, pharmacokinetics (PK), and pharmacodynamics (PD) (reduction of galactitol levels) of AT-007 in pediatric subjects with Classic Galactosemia (CG).

Read the detailed description

This is a randomized, double-blind, placebo-controlled study in pediatric subjects with CG. Children with CG ages 2 through 17 years will be enrolled. The study is designed to assess the clinical benefit using validated, standardized Clinical Outcome Assessments (COAs) as well as the safety, PK, and PD (reduction of galactitol levels) of AT-007 in pediatric subjects with CG. The study consists of 2 main parts, Part A and Part B, and an open-label extension (OLE).

Part A is an intra-patient dose escalation evaluating multiple ascending doses (MAD) of AT-007.

Part B is designed to assess the clinical benefits of long-term administration of AT-007 (at the optimum dose identified in Part A) on validated, standardized COAs.

Open-label extension (OLE) is an active treatment extension for patients who received placebo treatment in Part B.

02

Conditions studied

  • Classic Galactosemia

Keywords

  • Galactosemia
  • Classic Galactosemia
03

In context

Lead sponsor

Applied Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male
  • Female non-pregnant
  • Female non-lactating subjects aged ≥2 to \<18 years.
  • Diagnosis of Classic Galactosemia, confirmed by \<1% GALT (galactose-1-phosphate uridyltransferase) enzyme activity in erythrocytes, or a historical record of diagnosis of \<1% GALT enzyme activity.

Exclusion criteria

Exclusion:

  • Male/Female with no significant health problems (other than classic Galactosemia)
  • No other disease that would preclude participation in the study.
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Experimental: AT-007

    AT-007 The starting dose in Part A will be 5 mg/kg for all age groups. For each age group, Part B of the study will not start until the optimum dose evaluated in Part A has been identified

    Drug: AT-007

  • Placebo comparator
    Placebo

    Placebo given orally

    Other: Placebo

Interventions

  • DrugAT-007

    Treatment with AT-007 given orally

    Also known as: aldose reductase inhibitor

  • OtherPlacebo

    Placebo given orally

06

What researchers measure

Primary outcomes

  1. Global Statistical Test (GST)

    The primary endpoint is a GST of four components: 1) Behavioral Symptoms Index of the Behavioral Assessment Scale for Children 3 (BASC-3); 2) Activities of Daily Living from the BASC-3; 3) Oral Expression from the Oral and Written Language Skills-II (OWLS-II); 4) Listening Comprehension from the OWLS-II. Each individual component is also a secondary endpoint on their own with the test and scoring described below in the secondary endpoint section. For the GST, change from baseline using standardized z-scores is calculated for active versus placebo.

    Time frame: Month 6, Month 12 and Month 18

  2. Sensitivity Analysis of the Primary Endpoint (GST) with Cognition

    Sensitivity Analysis adding the National Institutes of Health Toolbox Cognition Battery (NIH-CB) test which measures cognition. NIH-CB is described below in the secondary endpoints. For the GST with cognition, change from baseline using standardized z-scores is calculated for active versus placebo.

    Time frame: Month 6, Month 12 and Month 18

  3. Sensitivity Analysis of the Primary Endpoint (GST) with Fine Motor Skills

    Sensitivity Analysis adding the National Institutes of Health Toolbox Motor Battery (NIH-MB) 9-Hole Pegboard test which measures fine motor skills. NIH-MB is described below in the secondary endpoints. For the GST with fine motor skills, change from baseline using standardized z-scores is calculated for active versus placebo.

    Time frame: Month 6, Month 12 and Month 18

Secondary outcomes

  1. Galactitol Level

    The change from baseline in plasma galactitol (Pharmacodynamic measure)

    Time frame: Month 1, Month 2, Month 3, Month 6, Month 12, and Month 18

  2. Behavioral Assessment System for Children-3 [Individual Components]

    Behavioral Assessment System for Children (BASC-3) has a normal range of 40-60 with the higher score showing more difficulty. There are multiple outcome scores included such as: Behavioral Symptoms Index, Activities of Daily Living, Withdrawal, Adapatability, Adaptive Skills, Socialization, and Functional Impairment Index.

    Time frame: Month 6, Month 12 and Month 18

  3. National Institute of Health Toolbox Cognition Battery

    Change from baseline in the NIH Toolbox Cognition Battery (NIH-CB). The NIH-CB uses multiple tests to evaluate Cognition and consists of tests of multiple constructs to yield individual ranking and demonstrate Cognitive Function Composite, Fluid Cognition Composite Sequence Memory, List Sorting, Pattern Comparison, and Crystallized Cognition Composite, Picture Vocabulary and Reading Recognition. This is standardized normal or 100 with a standard deviation of 10. Higher scores are better.

    Time frame: Month 6, Month 12 and Month 18

  4. Archimedes Spiral Drawing Test

    The Archimedes Spiral Drawing Test evaluates tremor on a scale of 0 (no tremor) to 4 (severe tremor).

    Time frame: Month 6, Month 12 and Month 18

  5. National Institute of Health Toolbox Motor Battery

    NIH Toolbox Motor Battery (NIH-MB) is a multiple of tests to determine fine motor skills using the 9-Hole Pegboard Test and gross motor skills using the Standing Balance Test. This is standardized normal or 100 with a standard deviation of 10. Higher scores are better.

    Time frame: Month 6, Month 12 and Month 18

  6. Scale for Assessment & Rating of Ataxia

    Scale for Assessment \& Rating of Ataxia (SARA) is 0-40, the higher the score the worse value

    Time frame: Month 6, Month 12 and Month 18

  7. Oral and Written Language Scales-II

    Oral and Written Language Scales-II (OWLS-II) has both an Oral Expression and Listening Comprehension score. Scores are 0-100 with a standard deviation of 15.

    Time frame: Month 6, Month 12 and Month 18

  8. Rate of Lens Opacity

    Onset and severity/progression of cataracts using the Lens Opacity System (LOCS) III, has a grading scale of 1-4, with 4 the most severe as assessed by the reviewer per standard criteria for anterior and posterior obstruction of the eye.

    Time frame: Month 6, Month 12 and Month 18

  9. Sexual maturation in female patients as indicated by Tanner Stage

    Sexual maturation in female patients as indicated by Tanner Stage 1- 4 which is the ranking of physical development in children, adolescents and adults. This defines physical measurements of development based on external primary and secondary sex characteristics, such as the size of the breasts, and development of pubic hair. This is assessed by physical exam with Stage 1 per-pubescent and Stage 4 post pubescent.

    Time frame: Month 6, Month 12 and Month 18

  10. Ovarian function in female patients determined by hormonal tests.

    Ovarian function in female patients is recorded by hormonal measures: FSH (follicle stimulating hormone), estradiol, and LH (luteinizing hormone).

    Time frame: Month 6, Month 12 and Month 18

Other outcomes

  1. Biomarker Analysis [Exploratory]

    This biomarker analysis will be performed to assess the levels of galactose and its other metabolites; Exploratory Endpoint

    Time frame: Month 1, Month 2, Month 3, Month 6, Month 12, and Month 18

  2. Bayley Scales of Infant and Toddler Development-4 [Exploratory]

    Bayley Scales of Infant and Toddler Development (Bayley-4) showing a score of 40 -160 with higher values showing more development. Exploratory Endpoint

    Time frame: Month 6, Month 12 and Month 18

  3. Vineland Adaptive Behavior Scales-3 [Exploratory]

    Vineland Adaptive Behavior Scales (Vineland-3) has a normal score of 100 and lower scores show developmental delay; Exploratory Endpoint

    Time frame: Month 6, Month 12 and Month 18

07

Study locations

3 sites
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Rare Disease Research Center
    Atlanta, Georgia 30318, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
08

References and documents

Publications

  • Bailey E, Phan H, Ahmad A, Thomas J, Ames EG, Pritchard AB, Quinonez SC, Wang S, Dayley C, Salt A, Pick C, Durrant A, Johnson S, Nicodemus-Johnson J, Dickson SP, Perfetti R, Hendrix SB, Shendelman S. Results of the ACTION-Galactosemia Kids Study to Evaluate the Effects of Govorestat in Pediatric Patients with Classic Galactosemia. J Clin Pharmacol. 2025 May;65(5):575-587. doi: 10.1002/jcph.6170. Epub 2024 Nov 21. PubMed 39569553 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Mar 2023, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2020
First posted
May 26, 2021
StartActual
Mar 20, 2021
Primary completionActual
Mar 3, 2023
CompletionActual
May 21, 2025
Last update
Oct 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04902781
Lead sponsor
Applied Therapeutics, Inc.
Responsible party
Sponsor
First posted
May 26, 2021
Start date
Mar 20, 2021
Primary completion
Mar 3, 2023
Completion
May 21, 2025
Last update
Oct 29, 2025

Study contacts

Susan E Waisbren, PhD
study chair · Harvard University
Jonathan W Mink, MD
study chair · University of Rochester

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Govorestat

Start the discussion